[CAS NO. 2684216-48-4] Gly3-VC-PAB-MMAE
PRODUCTS SPECIFICATIONS [2684216-48-4]
DESCRIPTION [2684216-48-4]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 1294.58 |
| Molecular Formula | C64H103N13O15 |
| SMILES | CC[C@@H]([C@H](N(C)C([C@@H](NC([C@@H](N(C)C(OCC1=CC=C(C=C1)NC([C@@H](NC([C@@H](NC(CNC(CNC(CN)=O)=O)=O)C(C)C)=O)CCCNC(N)=O)=O)=O)C(C)C)=O)C(C)C)=O)[C@H](OC)CC(N2[C@H]([C@H](OC)[C@H](C(N[C@@H]([C@H](C3=CC=CC=C3)O)C)=O)C)CCC2)=O)C |
Summary
Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs) [1] .
IC50 & Target
|
Auristatin |
In Vitro
ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years |
* The compound is unstable in solutions, freshly prepared is recommended.
Solvent & Solubility
DMSO : 200 mg/mL ( 154.49 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 0.7725 mL | 3.8623 mL | 7.7245 mL |
| 5 mM | 0.1545 mL | 0.7725 mL | 1.5449 mL |
| 10 mM | 0.0772 mL | 0.3862 mL | 0.7725 mL |